Journal
MOLECULAR PHARMACEUTICS
Volume 14, Issue 9, Pages 3059-3068Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.7b00282
Keywords
angiogenesis; enhanced permeability and enhanced effect; siVEGF delivery; PEGylation; antitumor therapy
Funding
- National Research Foundation of Korea [2014049587, 2015003019]
- Brain Korea 21 plus program [22A20130011095]
Ask authors/readers for more resources
Angiogenesis mainly mediated by upregulation of vascular endothelial growth factor (VEGF) provides a hallmark of rapidly proliferating tumor cells and an essential component of the tumor growth and microenvironment, making it a targetable process for antitumor therapy. RNA interference (RNAi) provides a very effective tool for developing antitumor therapies; however, its application to date has been hampered due to the lack of efficient small interfering RNA (siRNA) delivery systems in vivo. Here, we report a polymeric gene carrier system based on PEGylation of a cationic cysteine-ended 9-mer arginine oligopeptide (CR9C), which provides effective siRNA systemic delivery and specifically suppresses VEGF (siVEGF). The PEG500-CR9C/siVEGF oligopeptoplex provided improved blood circulation, enhanced protection from serum proteases, reduced uptake in the liver and kidneys, enhanced tumor targeting, and down-regulated intratumoral VEGF level, which comprehensively resulted in improved antitumor efficacy without significant toxicity in vivo. PEG500-CR9C has a great potential for safe and efficient siRNA delivery with diverse applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available